These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 36305021)

  • 1. PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application.
    Mastracci L; Grillo F; Parente P; Gullo I; Campora M; Angerilli V; Rossi C; Sacramento ML; Pennelli G; Vanoli A; Fassan M
    Pathologica; 2022 Oct; 114(5):352-364. PubMed ID: 36305021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical approach for PD-L1 evaluation in gastroesophageal cancer.
    Angerilli V; Fassan M; Parente P; Gullo I; Campora M; Rossi C; Sacramento ML; Pennelli G; Vanoli A; Grillo F; Mastracci L
    Pathologica; 2023 Apr; 115(2):57-70. PubMed ID: 36537078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.
    Okadome K; Baba Y; Yasuda-Yoshihara N; Nomoto D; Yagi T; Toihata T; Ogawa K; Sawayama H; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
    Cancer Sci; 2022 Feb; 113(2):399-410. PubMed ID: 34773342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy.
    Ji S; Chen H; Yang K; Zhang G; Mao B; Hu Y; Zhang H; Xu J
    Biomed Pharmacother; 2020 Sep; 129():110457. PubMed ID: 32887027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
    Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
    Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract.
    Baretton GB; Lordick F; ; Gaiser T; Hofheinz R; Horst D; Lorenzen S; Moehler M; Röcken C; Schirmacher P; Stahl M; Thuss-Patience P; Tiemann K
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16231-16238. PubMed ID: 37874352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.
    Liu W; Huo G; Chen P
    Immunotherapy; 2023 Jul; 15(10):751-771. PubMed ID: 37190983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
    Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
    Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
    Davis AA; Patel VG
    J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
    Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
    Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Immunotherapy in Esophageal and Gastric Cancer.
    Dedecker H; Teuwen LA; Vandamme T; Domen A; Prenen H
    Clin Colorectal Cancer; 2023 Jun; 22(2):175-182. PubMed ID: 37005190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for checkpoint inhibition in hematologic malignancies.
    Atanackovic D; Luetkens T
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expert consensus on PD-L1 expression testing in esophageal carcinoma in China].
    Xue LY; Li Y; Huang J; ; ; ; ;
    Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):291-297. PubMed ID: 37078210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
    Lefler DS; Snook AE; Bashir B
    Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.
    Lu Z; Yang S; Luo X; Shi Y; Lee JS; Deva S; Liu T; Chao Y; Zhang Y; Huang R; Xu Y; Shen Z; Shen L
    Gastric Cancer; 2022 Sep; 25(5):943-955. PubMed ID: 35778636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
    Cui C; Yu B; Jiang Q; Li X; Shi K; Yang Z
    Clin Exp Pharmacol Physiol; 2019 Jan; 46(1):3-10. PubMed ID: 30161295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
    De Meulenaere A; Vermassen T; Aspeslagh S; Huvenne W; Van Dorpe J; Ferdinande L; Rottey S
    Oral Oncol; 2017 Jul; 70():34-42. PubMed ID: 28622889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive potential and need for standardization of PD-L1 immunohistochemistry.
    Savic Prince S; Bubendorf L
    Virchows Arch; 2019 Apr; 474(4):475-484. PubMed ID: 30173280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.